期刊
ONCOLOGIST
卷 17, 期 5, 页码 732-739出版社
WILEY
DOI: 10.1634/theoncologist.2011-0368
关键词
Carcinoma; Chemoembolization; Fatigue; Hepatocellular; Quality of Life
类别
资金
- Ameritox
- Archimedes Pharmaceuticals
- Boston Scientific
- Covidien Mallinckrodt Inc.
- Endo Pharmaceuticals
- Forest Labs
- K-Pax Pharmaceuticals
- Meda Pharmaceuticals
- Medtronics
- Otsuka Pharma
- ProStrakan
- Purdue Pharma
- Salix
- St. Jude Medical
- National Science Council [NSC98-2314-B-002-103-MY3]
Objective. To (a) explore changes in physical and psychological distress and quality of life (QOL) and (b) identify the significant pre- and postdischarge factors related to changes in physical and mental domains of QOL over a period of 2 months in patients with hepatocellular carcinoma receiving one course of transarterial chemoembolization (TACE) treatment. Methods. A longitudinal prospective design was used, with participants recruited from a teaching hospital in Northern Taiwan. Data were collected three times: within 3 days prior to discharge (T0) and at the fourth (T1) and eighth (T2) weeks after discharge. A set of structured questionnaires was used to assess participants' QOL, symptom distress, anxiety, and depression. Changes in QOL and associated factors were examined using generalized estimating equations. Results. Eighty-nine patients were included in this study. Fatigue was reported to be the most distressful symptom after treatment. Overall QOL improved monthly after discharge. Change in physical QOL 2 months after TACE treatment was associated with age, diagnosis status, level of symptom distress, and depression after discharge. Change in mental QOL was significantly associated with gender, diagnosis status, and anxiety and depression after discharge. Conclusions. Health care providers should pay special attention to patients of older age, those who are male, and those who have higher levels of depression and anxiety after discharge. Designing personalized education programs before discharge for patients with newly diagnosed cancer versus those who have recurrent disease is suggested to help patients maintain a better QOL after discharge. The Oncologist 2012;17:732-739
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据